Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls

Orphanet Journal of Rare Diseases

Claire L Shovlin²  B Maneesha Silva³  Hannah L Devlin⁴  Anna E Hosman¹ 

[1] Academic Medical Center School of Medicine, Amsterdam, Netherlands;HHTIC London, Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK;Imperial College London School of Medicine, London, UK;Barts and the London School of Medicine and Dentistry, London, UK

关键词: Metastases;    Smoking;    SMAD4;    ALK1;    Endoglin;    Prostate;    Lung;    Liver;    Colorectal;    Breast;   

Others  :  863348
DOI  :  10.1186/1750-1172-8-195

 received in 2013-10-02, accepted in 2013-12-13,  发布年份 2013

【 摘 要 】

Background

Hereditary haemorrhagic telangiectasia (HHT) is inherited as an autosomal dominant trait, affects ~1 in 5,000, and causes multi-systemic vascular lesions and life-limiting complications. Life expectancy is surprisingly good, particularly for patients over 60ys. We hypothesised that individuals with HHT may be protected against life-limiting cancers.

Methods

To compare specific cancer rates in HHT patients and controls, we developed a questionnaire capturing data on multiple relatives per respondent, powered to detect differences in the four most common solid non skin cancers (breast, colorectal, lung and prostate), each associated with significant mortality. Blinded to cancer responses, reports of HHT-specific features allowed assignment of participants and relatives as HHT-subjects, unknowns, or controls. Logistic and quadratic regressions were used to compare rates of specific cancer types between HHT subjects and controls.

Results

1,307 participants completed the questionnaire including 1,007 HHT-subjects and 142 controls. The rigorous HHT diagnostic algorithm meant that 158 (12%) completed datasets were not assignable either to HHT or control status. For cancers predominantly recognised as primary cancers, the rates in the controls generally matched age-standardised rates for the general population. HHT subjects recruited through the survey had similar demographics to controls, although the HHT group reported a significantly greater smoking habit. Combining data of participants and uniquely-reported relatives resulted in an HHT-arm of 2,161 (58% female), and control-arm of 2,817 (52% female), with median ages of 66ys [IQR 53–77] and 77ys [IQR 65–82] respectively. In both crude and age-adjusted regression, lung cancers were significantly less frequent in the HHT arm than controls (age-adjusted odds ratio 0.48 [0.30, 0.70], p = 0.0012). Breast cancer prevalence was higher in HHT than controls (age-adjusted OR 1.52 [1.07, 2.14], p = 0.018). Overall, prostate and colorectal cancer rates were equivalent, but the pattern of colorectal cancer was modified, with a higher prevalence in younger HHT patients than controls.

Conclusions

These preliminary survey data suggest clinically significant differences in the rates of lung, breast and colorectal cancer in HHT patients compared to controls. For rare diseases in which longitudinal studies take decades to recruit equivalent datasets, this type of methodology provides a good first-step method for data collection.

【 授权许可】

   
2013 Hosman et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kjeldsen AD, Vase P, Green A: Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999, 245:31-39.
• [2]Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M, Nozaki J, Inoue S, Koizumi A: Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mut 2002, 19:140-148.
• [3]Plauchu H, de Chadarévian JP, Bideau A, Robert JM: Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989, 32(3):291-7.
• [4]Govani FS, Shovlin CL: Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009, 17:860-71.
• [5]Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R: International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011, 48:73-87.
• [6]Shovlin CL: Hereditary hemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010, 24:203-19.
• [7]Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL: Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS ONE 2013, 8(10):e76516.
• [8]Kjeldsen A, Kjeldsen J: Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000, 95:415-8.
• [9]Krings T, Ozanne A, Chng S, Alvarez H, Rodesch G, Lasjaunias P: Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day–60 years. Neuroradiology 2005, 47:711-20.
• [10]Shovlin CL, Jackson JE, Bamford KB, Jenkins IH, Benjamin AR, Ramadan H, Kulinskaya E: Primary determinants of ischemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia. Thorax 2008, 63:259-66.
• [11]Kjeldsen AD, Tørring PM, Nissen H, Andersen PE: Cerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia. Acta Neurol Scand 2013. 10.1111/ane.12167. [Epub ahead of print]
• [12]Hewes RC, Auster M, White RI: Cerebral embolism- first manifestation of pulmonary arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Cardiovasc Intervent Radiol 1985, 8:151-5.
• [13]Ference BA, Shannon TM, White RI Jr, Zawin M, Burdge CM: Life threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994, 106:1387-1392.
• [14]Shovlin CL, Sodhi V, McCarthy A, Lasjaunias P, Jackson JE, Sheppard MN: Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia suggested approach for obstetric services. BJOG 2008, 115:1108-15.
• [15]Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G, Lupinacci G, Brambilla G, Menozzi F, De Grazia F, Gazzaniga P, Inama G, Bonardi R, Blotta P, Forner P, Olivieri C, Perna A, Grosso M, Pongiglione G, Boccardi E, Pagella F, Rossi G, Zambelli A: Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic telangiectasia. Dig Dis Sci 2011, 56(7):2166-78.
• [16]Lerut J, Orlando G, Adam R, Sabbà C, Pfitzmann R, Klempnauer J, Belghiti J, Pirenne J, Thevenot T, Hillert C, Brown CM, Gonze D, Karam V, Boillot O: European Liver Transplant Association. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg 2006, 244:854-62.
• [17]Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jaïs X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O'Callaghan DS, Simonneau G, Soubrier F, Humbert M: Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010, 181:851-61.
• [18]Shovlin CL, Sulainam NL, Govani FS, Jackson JE, Begbie ME: Elevated Factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007, 98:1031-9.
• [19]Livesey JA, Manning R, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, Shovlin CL: Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary hemorrhagic telangiectasia. Thorax 2012, 67:328-33.
• [20]Brosens LA, van Hattem A, Hylind LM, Iacobuzio-Donahue C, Romans KE, Axilbund J, Cruz-Correa M, Tersmette AC, Offerhaus GJ, Giardiello FM: Risk of colorectal cancer in juvenile polyposis. Gut 2007, 56:965-7.
• [21]Schwenter F, Faughnan ME, Gradinger AB, Berk T, Gryfe R, Pollett A, Cohen Z, Gallinger S, Durno C: Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation. J Gastroenterol 2012, 47:795-804.
• [22]Devlin HL, Hosman AE, Shovlin CL: Antiplatelets and anticoagulants in hereditary hemorrhagic telangiectasia. New Engl J Med 2013, 368:876-8.
• [23]Sabbà C, Pasculli G, Suppressa P, D'Ovidio F, Lenato GM, Resta F, Assennato G, Guanti G: Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006, 99:327-34.
• [24]de Gussem EM, Edwards CP, Westermann CJJ, Faughnan ME, Mager JJ: Life expectancy of parents with hereditary hemorrhagic telangiectasia. Hematol Meet Rep 2009, 3(Suppl 4):11-2.
• [25]Goodwin J, Nisenbaum R, Edwards C, Faughnan ME: Survival in hereditary hemorrhagic telangiectasia. Hematol Meet Rep 2009, 3(Suppl 4):12.
• [26]Guttmacher AE, McKinnon WC, Taylor LA, Berg J, Porteous MEM, Korsenik J, Fayad PB, Shovlin C, Burdge CM, Jacobson B, Van Cutsem E, Westermann CJJ, Kjeldsen A, Vase P, White RI, McDonald J, Marchuk DA: The natural history of hereditary haemorrhagic telangiectasia: data from a patient questionnaire. Curaçao: Conference Proceedings for HHT Foundation Int., Scientific Meeting; 1997.
• [27]GLOBOCAN: Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. 2008. http://globocan.iarc.fr webcite
• [28]Cancer Research UK: CancerStats: Cancer Statistics for the UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/ webcite
• [29]Easey AJ, Wallace GM, Hughes JM, Jackson JE, Taylor WJ, Shovlin CL: Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for cerebral vascular malformations? Data from 22,061 years of HHT patient life. J Neurol Neurosurg Psych 2003, 74:743-8.
• [30]Silva BM, Hosman AE, Devlin HL, Shovlin CL: A questionnaire-based study suggests lifestyle and dietary factors influencing nosebleed severity in hereditary hemorrhagic telangiectasia (HHT). Laryngoscope 2013, 123:1092-9.
• [31]HHT Foundation International. http://www.hht.org webcite
• [32]Shovlin CL, Guttmacher AE, Buscarini E, Faughan M, Hyland R, Westermann CJJ, Plauchu H: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000, 91:66-7.
• [33]van Gent MW, Velthuis S, Post MC, Snijder RJ, Westermann CJ, Letteboer TG, Mager JJ: Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria? Am J Med Genet A 2013, 161:461-6.
• [34]World Fertility Data, United Nations Population Division. http://www.un.org/en/development/desa/population/theme/fertility/index.shtml webcite
• [35]Govani FS, Giess A, Mollet IM, Begbie ME, Jones M, Game L, Shovlin CL: Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia. Mol Syndromol 2013, 4:184-196.
• [36]McDonald J, Gedge F, Burdette A, Carlisle J, Bukjiok C, et al.: Multiple sequence variants in hereditary hemorrhagic telangiectasia cases: illustration of complexity in molecular diagnostic interpretation. J Mol Diagnostics 2009, 11(6):569-575.
• [37]Pece N, Vera S, Cymerman U, White R, Wrana J, Letarte M: Mutant endoglin in Hereditary Hemorrhagic Telangiectasia type I is transiently expressed intracellularly and is not a dominant negative. J Clin Invest 1997, 100:2568-2579.
• [38]Pece-Barbara N, Cymerman U, Vera S, Marchuk D, Letarte M: Expression analysis of four endoglin missense mutations suggests haploinsufficiency is the predominant mechanism for Hereditary Hemorrhagic Telangiectasia type I. Hum Mol Genet 1999, 8:2171-2181.
• [39]Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E, Wrana JL, Letarte M: Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 2005, 280:27800-27808.
• [40]Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, Becker L, Letarte M: Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000, 156:911-923.
• [41]Cymerman U, Vera S, Pece-Barbara N, Bourdeau A, White RI Jr, Dunn J, Letarte M: Identification of Hereditary Hemorrhagic Telangiectasia type I in newborns by protein expression and mutation analysis of endoglin. Pediatr Res 2000, 47:24-35.
• [42]Paquet ME, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C, Letarte M: Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 2001, 10:1347-1357.
• [43]Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Restrepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, Botella LM: Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat 2006, 27:295.
• [44]Seki T, Yun J, Oh SP: Arterial endothelium-specific activin receptor- like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003, 93:682-9.
• [45]Santibanez JF, Pérez-Gómez E, Fernandez-L A, Garrido-Martin EM, Carnero A, Malumbres M, Vary CP, Quintanilla M, Bernabéu C: The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis 2010, 31:2145-54.
• [46]Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN: Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 2013, 19:170-82.
• [47]Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H, Seon BK: Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009, 125:1446-53.
• [48]van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, Goumans MJ, ten Dijke P: Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 2012, 287:18551-61.
• [49]Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Páez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K: Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 2013, 210:563-79.
• [50]Henry LA, Johnson DA, Sarrió D, Lee S, Quinlan PR, Crook T, Thompson AM, Reis-Filho JS, Isacke CM: Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene 2011, 30:1046-58.
• [51]Quintanilla M, Ramirez JR, Pérez-Gómez E, Romero D, Velasco B, Letarte M, López-Novoa JM, Bernabéu C: Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Oncogene 2003, 22:5976-5985.
• [52]Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Wang A, Pérez-Barriocanal F, Arévalo M, Bernabéu C, Letarte M, López-Novoa JM: Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 2006, 69:845-54.
• [53]Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R: ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Mol Cancer Ther 2010, 9:379-388.
• [54]Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS: A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 2012, 18:4820-9.
• [55]Bernabeu C, Shovlin CL: TRC-105, an anti-endoglin chimeric mAb for the potential treatment of cancer. Thomson Reuters Pharma; https://www.thomson-pharma.com/portal/page/portal/Reports/drug_id=17606 webcite
• [56]Elphick A, Shovlin CL: Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Laryngoscope 2013. 10.1002/lary.24526
• [57]Berrington De González A, Darby S: Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004, 363:345-51.
• [58]Chodick G, Ronckers C, Shalev V, Ron E: Excess lifetime cancer mortality risk attributable to radiation exposure from computed tomography examinations in children. Isr Med Assoc J 2007, 9:584-7.
• [59]Rice H, Frush D, Farmer D, Waldhausen J: APSA Education Committee Review of radiation risks from computed tomography: essentials for the pediatric surgeon. J Pediatr Surg 2007, 42:603-7.
• [60]Thierry-Chef I, Simon SL, Land CE, Miller DL: Radiation dose to the brain and subsequent risk of developing brain tumors in pediatric patients undergoing interventional neuroradiology procedures. Radiat Res 2008, 170:553-65.
• [61]Ma S, Kong B, Liu B, Liu X: Biological effects of low-dose radiation from computed tomography scanning. Int J Radiat Biol 2013, 89:326-33.